Lineage Cell says first OpRegen development milestone under Roche pact achieved

According to a regulatory filing, as previously reported, in December 2021, Lineage Cell Therapeutics (LCTX) entered into a collaboration and license agreement with Genentech, Inc. and Roche (RHHBY) under which Lineage’s lead cell therapy program known as OpRegen is being developed for the treatment of ocular disorders, including geographic atrophy secondary to age-related macular degeneration. OpRegen is currently being evaluated in a Phase 2a multicenter clinical trial, known as “GAlette,” in patients with GA secondary to AMD. On November 20, 2025, the first development milestone under the Roche Agreement was achieved based on manufacturing and clinical advancements related to the OpRegen cell therapy program. This event triggered a $5M milestone payment to Lineage, which is expected to be received by us within 30 days. As previously reported, approximately 24.1% and 21.5% of the milestone payment will be paid to the Israel Innovation Authority and to Hadasit Medical Research and Development, respectively, in accordance with the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and in accordance with agreements between Lineage’s subsidiary, Cell Cure Neuroscience Ltd., and Hadasit, respectively.